This is a working overview of Ipamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Kevin Darnell Hart (born July 6, 1979) is an American comedian and actor. After winning several stand-up comedy competitions, Hart had his first breakthrough when Judd Apatow cast him in a recurring role on the TV series Undeclared (2001). Hart's comedic reputation continued to grow with the release of his first stand-up album I'm a Grown Little Man (2009). He has since released four more comedy albums: Seriously Funny (2010), Laugh at My Pain (2011), Let Me Explain (2013), and What Now? (2016). As an actor, Hart has had roles in films such as Paper Soldiers (2002), Scary Movie 3 (2003), Soul Plane (2004), In the Mix (2005), Little Fockers (2010), Think Like a Man (2012), Grudge Match (2013), Ride Along (2014), About Last Night (2014), Get Hard (2015), Central Intelligence (2016), The Secret Life of Pets film franchise (2016–2019), Ride Along 2 (2016), Captain Underpants: The First Epic Movie (2017), the Jumanji film franchise (2017–present), and Night School (2018). He also created and starred as a fictionalized version of himself in Real Husbands of Hollywood (2013–2016). In 2017, he launched the Laugh Out Loud Network, a subscription video streaming service in partnership with Lionsgate. Hart has received numerous accolades including the Mark Twain Prize for American Humor in 2024, and nominations for two Grammy Awards and four Primetime Emmy Awards. In 2015, Time magazine named him on its annual list of the 100 most influential people in the world.
== Board of directors == The board of directors is composed of thirteen members, in office until the approval of the financial statements at 31 December 2020, with Alberto Vacchi in the role of chairman and executive CEO. Marco Vacchi is the honorary president.
== The aerobic 4S pathway == The 4S pathway is a sulfur-specific metabolic pathway of oxidative desulfurization that converts dibenzothiophene (DBT) into 2-hydroxybiphenyl and sulfite. It uses a total of four NADH molecules (three required by DszD to generate FMNH2 and a fourth to regenerate the FMN-oxide byproduct of DszA) and three molecules of oxygen, thus producing NAD+ and water as byproducts.
=== Homonuclear nuclear magnetic resonance === With unlabelled protein the usual procedure is to record a set of two-dimensional homonuclear nuclear magnetic resonance experiments through correlation spectroscopy (COSY), of which several types include conventional correlation spectroscopy, total correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY). A two-dimensional nuclear magnetic resonance experiment produces a two-dimensional spectrum. The units of both axes are chemical shifts. The COSY and TOCSY transfer magnetization through the chemical bonds between adjacent protons. The conventional correlation spectroscopy experiment is only able to transfer magnetization between protons on adjacent atoms, whereas in the total correlation spectroscopy experiment the protons are able to relay the magnetization, so it is transferred among all the protons that are connected by adjacent atoms. Thus in a conventional correlation spectroscopy, an alpha proton transfers magnetization to the beta protons, the beta protons transfers to the alpha and gamma protons, if any are present, then the gamma proton transfers to the beta and the delta protons, and the process continues. In total correlation spectroscopy, the alpha and all the other protons are able to transfer magnetization to the beta, gamma, delta, epsilon if they are connected by a continuous chain of protons. The continuous chain of protons are the sidechain of the individual amino acids.
=== Biological detection === The discovery of radiative recombination in aluminum gallium nitride (AlGaN) alloys by U.S. Army Research Laboratory (ARL) led to the conceptualization of UV light-emitting diodes (LEDs) to be incorporated in light-induced fluorescence sensors used for biological agent detection. In 2004, the Edgewood Chemical Biological Center (ECBC) initiated the effort to create a biological detector named TAC-BIO. The program capitalized on semiconductor UV optical sources (SUVOS) developed by the Defense Advanced Research Projects Agency (DARPA). UV-induced fluorescence is one of the most robust techniques used for rapid real-time detection of biological aerosols. The first UV sensors were lasers lacking in-field-use practicality. In order to address this, DARPA incorporated SUVOS technology to create a low-cost, small, lightweight, low-power device. The TAC-BIO detector's response time was one minute from when it sensed a biological agent. It was also demonstrated that the detector could be operated unattended indoors and outdoors for weeks at a time. Aerosolized biological particles fluoresce and scatter light under a UV light beam. Observed fluorescence is dependent on the applied wavelength and the biochemical fluorophores within the biological agent. UV induced fluorescence offers a rapid, accurate, efficient and logistically practical way for biological agent detection.
Sources: en.wikipedia.org
=== Protein synthesis === EF-Tu participates in the polypeptide elongation process of protein synthesis. In prokaryotes, the primary function of EF-Tu is to transport the correct aa-tRNA to the A-site of the ribosome. As a G-protein, it uses GTP to facilitate its function. Outside of the ribosome, EF-Tu complexed with GTP (EF-Tu • GTP) complexes with aa-tRNA to form a stable EF-Tu • GTP • aa-tRNA ternary complex. EF-Tu • GTP binds all correctly-charged aa-tRNAs with approximately identical affinity, except those charged with initiation residues and selenocysteine. This can be accomplished because although different amino acid residues have varying side-chain properties, the tRNAs associated with those residues have varying structures to compensate for differences in side-chain binding affinities. The binding of an aa-tRNA to EF-Tu • GTP allows for the ternary complex to be translocated to the A-site of an active ribosome, in which the anticodon of the tRNA binds to the codon of the mRNA. If the correct anticodon binds to the mRNA codon, the ribosome changes configuration and alters the geometry of the GTPase domain of EF-Tu, resulting in the hydrolysis of the GTP associated with the EF-Tu to GDP and Pi. As such, the ribosome functions as a GTPase-activating protein (GAP) for EF-Tu. Upon GTP hydrolysis, the conformation of EF-Tu changes drastically and dissociates from the aa-tRNA and ribosome complex.
=== Nonprofit organizations === In the 2020s, several nonprofit organizations have emerged in the U.S. and Europe to focus on AI safety and related public policies, including the Alliance for Secure AI, Future of Life Institute, and Public First Action. Such groups often function as Silicon Valley watchdogs and advocate for specific federal, state, or local regulations. They also compete with industry groups such as Leading the Future, which advocate for the deregulation of AI companies.
== See also == ADME, an acronym in pharmacokinetics and pharmacology standing for absorption, distribution, metabolism, and excretion Biopharmaceutics Classification System Enteral administration Partition coefficient
Per Baseball Reference, Bagwell's 79.6 Wins Above Replacement (WAR) ranks sixth-most all-time among first basemen, trailing only Lou Gehrig, Albert Pujols, Jimmie Foxx, Cap Anson, and Roger Connor. He spent the first nine seasons of his career (1991–99) playing home games at the Astrodome, notorious for its reputation as the toughest park in which to hit when baseball was still played there. However, during those nine years, his production at home was nearly identical to his production on the road. In that same period of time, his 160 OPS+ was fourth behind Bonds, McGwire, and Frank Thomas; his 56.7 WAR was third behind Bonds and Ken Griffey Jr. From 1994 to 2000, a span including his age-26 through age-32 seasons, he averaged 41 home runs and 41 doubles per 162 games while batting .309, .433 OBP, and .593 SLG for a 167 OPS+. Over his career, Bagwell batted at least .300 six times, amassed a 1.000 OPS five times, collected at least 30 home runs eight times, 100 RBI eight times, 100 runs scored nine times, and 100 walks seven times. He is the only player in history to achieve six consecutive seasons (1996–2001) with each of 30 home runs, 100 RBI, 100 runs scored, and 100 walks. Bagwell had seven seasons with 30 home runs and 100 walks; the only players with more are Gehrig, Ruth, Williams, Jim Thome, and Thomas. Bagwell is one of 12 players in MLB history to hit at 400 home runs and attain a career on-base percentage of at least .400. The only National League first baseman to reach the 30–30 club, he is the only first baseman in history to do it twice.
The Drug Enforcement Administration (DEA) states, as an analogue of methcathinone, possession of mephedrone can be controlled by the Federal Analog Act, but according to the Los Angeles Times, this only applies if it is sold for human consumption. Several cities and states, such as New York state, have passed legislation to specifically list mephedrone as illegal, but in most areas it remained legal, so long as it is not sold for human consumption, so retailers described it as 'bath salts'. In September 2011, The DEA began using its emergency scheduling authority to temporarily control mephedrone. Except as authorised by law, this action made possessing and selling mephedrone or the products that contain it illegal in the US for at least one year while the DEA and the United States Department of Health and Human Services conduct further study. Control of these compounds became permanent on 9 July 2012, via passage of the Synthetic Drug Abuse Prevention Act of 2012.
Sources: en.wikipedia.org
Gingras research focuses on the development of experimental and bioinformatics approaches for functional proteomics, with a focus on protein-protein and proximity interactions. She applies these tools to the study of signaling pathways in health and disease and in mapping the physical organization of the dynamic proteome. Some of her work focuses on the consequence of disease-associated mutations on the interactions established by proteins. In addition to proteomics, Gingras laboratory has interest in studying human protein phosphatase and their systematic interactions and has now expanded into the field of systems biology.
Neptunium at The Periodic Table of Videos (University of Nottingham) Lab builds world's first neptunium sphere Archived 2006-09-25 at the Wayback Machine, U.S. Department of Energy Research News NLM Hazardous Substances Databank – Neptunium, Radioactive Neptunium: Human Health Fact Sheet Archived 2004-02-06 at the Wayback Machine C&EN: It's Elemental: The Periodic Table – Neptunium
Attempts to bypass that issue by infusing patients in clinical tests with very high doses of GLP-1—in order to overcome its rapid metabolism in the bloodstream—had produced extremely severe nausea, followed by immediate vomiting. Eng's employer, the U.S. Department of Veterans Affairs, turned out to have no interest in obtaining a drug patent on exendin-4, so Eng filed the patent application himself in 1993. He then spent three years on fruitless efforts to persuade the pharmaceutical industry to develop exendin-4 into a drug. Jens Juul Holst, a GLP-1 expert, later recalled seeing the skepticism which Eng encountered when he tried to present his work on a poster at industry conferences: "He was extremely frustrated ... Nobody was interested in his work. None of the important people. It was too strange for people to accept". At a 1996 American Diabetes Association conference in San Francisco, Eng finally caught the attention of scientist Andrew Young of Amylin Pharmaceuticals, who immediately recognized exendin-4's potential and arranged for his company to license Eng's patent. Young was excited to see Eng's poster at the conference summarizing his findings, but then noticed an Eli Lilly and Company executive reading the same poster, and he became worried that Lilly might beat Amylin to a license.
Merabishvili said that Russian troops passed the Roki Tunnel at 3:00 AM on 7 August because they couldn't be photographed in the darkness of the night. He cited Dmitry Sanakoev as having reported that Russia supplied tanks during the cloudy days so Americans would not record the movement of tanks from Russia into South Ossetia. Merabishvili said that the government had no choice: "If we lost the territory without resistance, the public society of Georgia would not forgive us." Merabishvili suggested that Georgia won time by fighting back the Russian troops and saved Tbilisi. On 25 November 2008, Erosi Kitsmarishvili, Georgia's former ambassador to Russia, gave a testimony to a parliamentary commission in which he said that Georgian authorities were preparing for the conflict. According to Kitsmarishvili, he was told by Georgian officials in April 2008 that the United States approved a war in Abkhazia, but later the Georgian authorities made the decision to launch the war in South Ossetia. According to him, "Russia was ready for this war, but the Georgian leadership started the military action first."
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.